$1.18 Billion is the total value of Eversept Partners, LP's 69 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 42.4% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| TEVA | Sell | TEVA PHARMACEUTICAL INDS LTDsponsored ads | $70,911,267 | +22.8% | 6,952,085 | -9.3% | 6.00% | +24.3% |
| HZNP | Sell | HORIZON THERAPEUTICS PUB L | $23,810,737 | -51.3% | 205,815 | -56.7% | 2.02% | -50.7% |
| CYH | Sell | COMMUNITY HEALTH SYS INC NEW | $20,723,655 | -35.3% | 7,146,088 | -1.8% | 1.75% | -34.5% |
| VERA | Sell | VERA THERAPEUTICS INCcl a | $20,270,084 | -27.5% | 1,478,489 | -15.1% | 1.72% | -26.6% |
| CLDX | Sell | CELLDEX THERAPEUTICS INC NEW | $16,185,695 | -39.3% | 588,143 | -25.1% | 1.37% | -38.5% |
| AMRX | Sell | AMNEAL PHARMACEUTICALS INC | $11,161,849 | -31.6% | 2,644,988 | -49.8% | 0.94% | -30.8% |
| PCVX | Sell | VAXCYTE INC | $9,708,121 | -0.7% | 190,430 | -2.7% | 0.82% | +0.6% |
| AMRN | Sell | AMARIN CORP PLCspons adr new | $7,757,325 | -37.9% | 8,431,875 | -19.7% | 0.66% | -37.2% |
| Sell | NEWAMSTERDAM PHARMA COMPANYordinary shares | $6,110,717 | -25.8% | 660,618 | -4.6% | 0.52% | -24.9% | |
| XBI | Sell | SPDR SER TRput | $5,841,600 | -22.0% | 80,000 | -11.1% | 0.49% | -21.1% |
| MCRB | Sell | SERES THERAPEUTICS INC | $5,599,083 | -62.0% | 2,352,556 | -23.5% | 0.47% | -61.5% |
| ICLR | Sell | ICON PLC | $5,170,758 | -71.2% | 20,998 | -70.7% | 0.44% | -70.8% |
| IFRX | Sell | INFLARX NV | $5,177,881 | -39.4% | 1,737,544 | -9.3% | 0.44% | -38.7% |
| AMN | Sell | AMN HEALTHCARE SVCS INCput | $4,259,000 | -58.9% | 50,000 | -47.4% | 0.36% | -58.5% |
| PNTG | Sell | PENNANT GROUP INC | $4,072,456 | -23.2% | 365,899 | -15.2% | 0.34% | -22.1% |
| MOH | Sell | MOLINA HEALTHCARE INC | $4,011,406 | -37.3% | 12,234 | -42.4% | 0.34% | -36.6% |
| RGEN | Sell | REPLIGEN CORP | $2,568,489 | -72.5% | 16,153 | -75.6% | 0.22% | -72.2% |
| MEDP | Sell | MEDPACE HLDGS INC | $2,136,313 | -42.8% | 8,823 | -43.3% | 0.18% | -42.2% |
| BDTX | Sell | BLACK DIAMOND THERAPEUTICS I | $967,566 | -55.2% | 337,131 | -21.1% | 0.08% | -54.4% |
| FGEN | Exit | FIBROGEN INC | $0 | – | -5,600 | -100.0% | -0.00% | – |
| FGEN | Exit | FIBROGEN INCput | $0 | – | -38,800 | -100.0% | -0.01% | – |
| SBTX | Exit | ARS PHARMACEUTICALS INC | $0 | – | -48,788 | -100.0% | -0.03% | – |
| URGN | Exit | UROGEN PHARMA LTD | $0 | – | -74,797 | -100.0% | -0.06% | – |
| ZLAB | Exit | ZAI LAB LTDadr | $0 | – | -55,176 | -100.0% | -0.13% | – |
| EOLS | Exit | EVOLUS INC | $0 | – | -228,679 | -100.0% | -0.14% | – |
| Exit | GOHEALTH INCcl a new | $0 | – | -104,820 | -100.0% | -0.17% | – | |
| PRTK | Exit | PARATEK PHARMACEUTICALS INC | $0 | – | -1,327,857 | -100.0% | -0.24% | – |
| EHTH | Exit | EHEALTH INC | $0 | – | -503,079 | -100.0% | -0.34% | – |
| KURA | Exit | KURA ONCOLOGY INC | $0 | – | -450,622 | -100.0% | -0.40% | – |
| XENE | Exit | XENON PHARMACEUTICALS INC | $0 | – | -171,378 | -100.0% | -0.55% | – |
| MODN | Exit | MODEL N INC | $0 | – | -223,168 | -100.0% | -0.66% | – |
| ABCM | Exit | ABCAM PLCads | $0 | – | -499,394 | -100.0% | -1.02% | – |
| CTLT | Exit | CATALENT INC | $0 | – | -356,875 | -100.0% | -1.29% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AMARIN CORP PLC | 21 | Q3 2023 | 12.5% |
| DANAHER CORPORATION | 21 | Q3 2023 | 8.1% |
| AFFIMED N V | 20 | Q3 2023 | 0.9% |
| ARGENX SE | 19 | Q3 2023 | 2.0% |
| GSK PLC | 18 | Q2 2022 | 13.1% |
| ASCENDIS PHARMA A/S | 18 | Q1 2022 | 7.7% |
| SANOFI | 18 | Q4 2022 | 7.2% |
| ENSIGN GROUP INC | 18 | Q1 2022 | 8.6% |
| CENTENE CORP DEL | 18 | Q3 2023 | 1.5% |
| ZOGENIX INC | 17 | Q4 2021 | 12.4% |
View Eversept Partners, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Cabaletta Bio, Inc. | February 14, 2023 | 282,874 | 1.0% |
| Teligent, Inc.Sold out | February 16, 2021 | 0 | 0.0% |
| Teligent, Inc. | February 14, 2020 | 4,501,799 | 8.4% |
View Eversept Partners, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR/A | 2023-11-08 |
| 13F-HR/A | 2023-11-08 |
| 13F-HR/A | 2023-11-08 |
| 13F-HR/A | 2023-11-08 |
| 13F-HR/A | 2023-11-08 |
| 13F-HR/A | 2023-11-08 |
| 13F-HR/A | 2023-11-08 |
View Eversept Partners, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.